AGP Executive Report
Last update: 8 hours agoObesity drug update: AstraZeneca’s oral weight-loss candidate elecoglipron showed dose-dependent results in a Phase 2 trial, with the highest dose group averaging about 10.5% weight loss at 26 weeks versus 0.6% on placebo, offering a potential pill alternative to injections. Infection care in focus: A real-world study in Chinese patients with invasive pulmonary fungal infection highlights posaconazole exposure variability and links subtherapeutic levels to poorer outcomes, reinforcing the need for therapeutic drug monitoring. Public health & safety: Taiwan prosecutors charged a school bus driver with multiple sexual offences after alleged religious deception; authorities are also investigating a possible link to HIV infections among victims. Care workforce rights: Labor groups urged Taiwan to let household migrant caregivers be hired and managed by long-term care agencies, arguing it would reduce overwork and improve protection for care recipients. Fertility warning for Taiwan: A new analysis argues Taiwan needs a low-fertility strategy beyond incentives, stressing governance planning for a structural baseline. AI infrastructure with health implications: Schneider Electric and Foxconn announced collaboration to scale next-generation AI data centers, aiming for faster, more efficient, and more sustainable power and cooling.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
